ABSTRACT

Introduction: In the last decades chronic obstructive pulmonary disease (COPD) has an increasing occurrence in Mexico, making it an important area of expenditure for the health sector. As control of exacerbations are a keystone from the clinical and economic point of view, it’s important to evaluate the anticholinergics to define which is the most cost-effective.
Material and methods: A Markov model was developed with a time horizon of 1 year. The main health outcome measure was the number of exacerbations prevented for both tiotropium and ipratropium which was 65 and 54% respectively, based on a clinical trial. Cost were estimated using institutional (IMSS) prices and considering: diagnosis, ambulatory treatment and mild, moderate or severe exacerbation’s treatment.
Results: Tiotropium is a dominant therapy for the treatment of COPD having a higher effectiveness and lower average costs incurred. Incremental cost-effectiveness ratio shows a saving $7,180 mxp with tiotropium.
Conclusions: Tiotropium clearly shows clinical and economic benefit reducing costs of treatment for patients with COPD and improving health outcomes.

KEYWORDS

Pharmacoeconomics, bronchodilator agents, tiotropium bromide, chronic obstructive pulmonary disease.

REFERENCES

1. Sansores RH, Ramírez-Venegas A. Segundo Consenso Mexicano para el diagnóstico y tratamiento de la EPOC. Rev Inst Nal Enf Resp Mex 2003; 16(Supl): 7-50.

2. Menezes AM, Pérez-Padilla R, Jardín JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (The PLATINO study): a prevalence study. Lancet 2005; 366: 1875-1881.

3. Grupo de Trabajo de la Asociación Latinoamericana del Tórax (ALAT). Actualización de las recomendaciones ALAT sobre la exacerbación infecciosa de la EPOC. Arch Bronconeumol 2004; 40: 315-325.

4. Tovar-Guzmán VJ, López-Antuñano FJ, Rodríguez-Salgado N. Recent trends in mortality due to chronic obstructive pulmonary disease (COPD) in Mexico, 1980-2002. Arch Med Res 2005; 36: 65-69.

5. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419-458.

6. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24: 1043-1053.

7. García-Ruiz AJ, Leiva-Fernández F, Martos-Crespo F. Análisis del coste-eficacia del tiotropio frente al ipratropio y salmeterol. Arch Bronconeumol 2005; 41: 242-248.

8. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J 2002; 19: 209-216.

9. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax 2006; 61: 854-862.

10. Instituto Mexicano del Seguro Social (IMSS) compró bienes terapéuticos. Disponible en: http://200.34.143.57:8080/wijsp/PDF_IMSS/IMSSComproBienesTerapeuticos.pdf Consultado el 17 de enero de 2006.

11. Secretaría General del IMSS. Costos unitarios para la determinación de créditos fiscales derivados de capitales constitutivos, inscripciones improcedentes y atención a no derechohabientes. Diario Oficial de la Federación, 9 de marzo de 2004.

12. Consejo Nacional de Población. México en cifras. Proyecciones de Población 2000-2050. Disponible en URL: www.inegi.com. Consultado el 20 enero 2006.

13. Instituto Mexicano del Seguro Social. Información estadística en salud. Población adscrita a médico familiar. Total nacional 2004. Disponible en URL: http://www.imss.gob.mx/dpm/dties/Celula.aspx? ID=SC01_01_00_01_02&OPC=opc02&SRV=SRV02&Men=1

14. Oostenbrink JB, Rutten-van Molken MP, Al MJ, Van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 241-249.

15. Oostenbrink JB, Rutten-van Molken MP, Monz BU, FitzGerald JM. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8: 32-46.

16. Schramm W. Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease. Schweiz Rundsch Med Prax 2005; 94: 1803-1810.

17. Navarro-Reynoso F. Efecto de las combinaciones salbutamol-ipratropio y salbutamol-tiotropio inhalados y teofilina vía oral en pacientes con EPOC. Análisis de costo/efectividad. Rev Inst Nal Enf Resp Mex 2006; 19: 122-126.